flaherty-icon-clr

CME
This issue features IPF Treatment Q&A, a review of a recently published article, Diagnostic Dilemmas (available for credit), and reviews recently released materials and upcoming events.

Kevin Flaherty, MD, MS; Marilyn Glassberg, MD; and Imre Noth, MD

 

In This Issue:

1. IPF Treatment Q&A

2. Publication Review
  3. Diagnostic Dilemmas

 

flaherty-icon-title
 flaherty-icon-main  

Dr. Kevin Flaherty, MD, MS answers common questions related to the newly approved treatments for IPF

Kevin Flaherty, MD, MS, University of Michigan Health System

  1. The primary efficacy results for pirfenidone and nintedanib seem to be quite close. What are the main safety considerations for each drug and how do these guide the choice for an individual patient?
    Listen Listen

  2. What are the major considerations for adding pirfenidone or nintedanib to multiple medications that many of my patients are already on?
    Listen Listen

  3. How will the recent drug approvals change the role of ILD centers?
    Listen Listen

  4. Some of my patients have received other medications for IPF. If they are stable on NAC or corticosteroids should I switch to one of the newly-approved drugs?
    Listen Listen

  5. How do the drug approvals impact lung transplant decisions?
    Listen Listen

  6. Should we prescribe nintedanib or pirfenidone for patients with advanced IPF?
    Listen Listen

glass-icon-title
glassberg-icon-main  

A phase 1b study of placenta-derived mesenchymal stromal cells in patients with idiopathic pulmonary fibrosis
Chambers DC, Enever D, Ilic N, et al. A phase 1b study of placenta-derived mesenchymal stromal cells in patients with idiopathic pulmonary fibrosis. Respirology. 2014;19(7):1013-1018.

Marilyn Glassberg, MD, University of Miami Health System

Continue


noth-icon-title
noth-icon-main  

cme-ce
Dr. Noth applies the lessons of guideline-based diagnosis to a real patient. Which findings confirm or rule out IPF? What are the implications of the diagnosis for Alex’s management plan?

Imre Noth, MD, The University of Chicago Medicine

Continue

 

Access other Therapeutic Areas: